ISSN 1564-4170 SERIES GENDER AFFAIRS 166 Effects of countercyclical policies on women's and men's incomes during the COVID-19 pandemic A gender analysis of personal taxes and transfers in Colombia, Ecuador and the Plurinational State of Bolivia Diego Collado Nicole Bidegain Thank you for your interest in this ECLAC publication Please register if you would like to receive information on our editorial products and activities. When you register, you may specify your particular areas of interest and you will ga ...

Core Viewpoint - The article emphasizes the importance of agricultural intellectual property rights (IPR) and highlights the role of South China Agricultural University in promoting and protecting these rights as a means to unlock the "invisible wealth" of agricultural products [1][4]. Group 1: Importance of Agricultural Intellectual Property - Agricultural intellectual property rights, also known as agricultural IPR, refer to the exclusive rights enjoyed by individuals or organizations over their intellectual achievements in the agricultural sector [6][7]. - These rights encompass various forms, including new plant varieties, geographical indications, agricultural patents, trademarks, copyrights, and trade secrets [7][8]. - The significance of agricultural IPR has been recognized as a strategic resource for national agricultural development and a core element in international agricultural competition [13][14]. Group 2: Initiatives by South China Agricultural University - South China Agricultural University has established a knowledge property rights research center, becoming the first university-level IPR research institution among agricultural and forestry colleges in China [20][21]. - The university has initiated the establishment of a modern seed industry IPR service center in collaboration with the Guangdong Seed Association, completing numerous agricultural patent reports annually [24][25]. - The university's variety rights authorization ranks second among agricultural and forestry universities in China, contributing to the development of first-class disciplines [26]. Group 3: Legal and Policy Contributions - The university has developed and implemented management measures for geographical indications, enhancing the legal environment for economic development in the region [30][32]. - It has also drafted support measures for modern agricultural high-quality development in Nansha District, positioning it as a national leader in seed industry support [34]. - The university's involvement in legal cases related to plant variety rights has been recognized as a typical case for judicial protection of seed industry IPR [36]. Group 4: Educational and Outreach Efforts - The university conducts various educational programs and courses related to agricultural IPR, contributing to the development of a first-class seed science and engineering program [43][44]. - It organizes forums and seminars to enhance awareness and understanding of agricultural IPR among stakeholders, including industry representatives and legal professionals [56][58]. - The university aims to support the development of an innovative economy and a brand economy in agriculture through the protection of plant variety rights and geographical indications [58][59].

Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount e.g., net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions and wide moat compounders). Sign up here to get sta ...

Core Insights - Moore Law, PLLC is investigating potential claims against OSI Systems, Inc. following a report from Culper Research that raises serious allegations about the company's financial disclosures and growth claims [1][2]. Group 1: Allegations and Investigations - Culper Research published a report on March 13, 2025, alleging that OSI's reported growth in Mexico revenues is "largely an illusion" [2]. - The report accuses OSI of downplaying U.S. Department of Justice investigations by providing "deliberately vague and misleading disclosures" [2]. - Following the report's publication, OSI's stock price fell by $6.35 per share, or 3.5%, closing at $175.31 per share on the same day [2]. Group 2: Company Background - OSI Systems, Inc. is publicly traded on NASDAQ under the ticker OSIS [1]. - Moore Law, PLLC specializes in holding corporate officers and directors accountable for various forms of corporate misconduct, including breaches of fiduciary duty and fraud [3].

有很多习惯，我们知道它对健康不利，但总会"不自觉"地放纵自己，比如熬夜、吃高热量的垃圾食品等等—— 但其实，这些坏习惯对我们健康的危害比想象中更严重。 首先，《Nature》子刊的一篇研究论文表明，一系列环境因素，包括生活方式 （例如吸烟、运动锻炼） 和生活条 件，对健康和衰老的影响比遗传因素的影响更大。 其次，睡眠作为人体最基本的生理需求之一，其质量的高低直接关系到免疫系统的功能和整体健康状态。一项 发表在《The Journal of Immunology》的研究指出，即使是短暂的一夜不睡，也会对免疫系统产生显著的负面影 响，使单核细胞的特征发生改变，进而引发慢性炎症和相关疾病的风险增加。 最后，饮食习惯对健康的影响也不容小觑。另一项发表在《Nature》子刊的研究显示，即使是短期的高热量饮 食，也会对大脑结构和功能产生长期的不良影响。 这些研究为我们提供了关于生活习惯对健康影响的有力证据，同时，它们不仅为我们敲响了警钟，也为改善健 康提供了新的方向。 生活方式的影响，远超基因 虽然人类的人均寿命已经突破了80岁，但是我们关于衰老的认知仍然在被不断颠覆——2025年2月19日，牛 津大学的研究人员在国际顶 ...

Core Insights - Solis Agrosciences has appointed Crystal Winkeler as Chief Business Officer to enhance its commercial team and drive growth initiatives [1][2] - Winkeler brings extensive experience from her previous roles, including leading investments at BioGenerator Ventures and co-founding Canopy Biosciences [2][3] - The company has shown significant progress in the AgTech sector, expanding its management team and launching new product offerings [6] Company Developments - Solis Agrosciences has secured a license for the Pairwise Fulcrum™ Platform and entered the whole-genome-sequencing market through the acquisition of Ferris Genomics [6] - The company has attracted new investments from Cultivation Capital and has significantly increased its sales [6] - Solis operates within the 39 North AgTech Innovation District in St. Louis, Missouri, focusing on high-quality AgTech research services [8][10] Leadership and Expertise - Crystal Winkeler is recognized for her ability to build business relationships and her scientific expertise, which will be beneficial for Solis [2][3] - Winkeler has a Ph.D. in Molecular Cell Biology from Washington University, adding to her qualifications [5] - Previous leadership roles include managing a team of over 40 at Canopy Biosciences and leading due diligence for seed investments at BioGenerator Ventures [3][4] Investment Landscape - Major investors in Solis include Hermann Companies, Cultivation Capital, and BioGenerator Ventures, among others [7] - Cultivation Capital is noted for being an active early-stage venture capital firm, having invested in over 150 companies since its inception [9]

Core Viewpoint - Value Line, Inc. has announced an 8.3% increase in its quarterly dividend, marking the 11th consecutive yearly increase, with the new dividend set at $0.325 per common share, payable on May 12, 2025 [1] Company Overview - Value Line is a prominent provider of investment research, with its Investment Survey being one of the most widely utilized sources of independent equity research [2] - The company publishes proprietary investment research in both print and digital formats [2] Specialized Services - Value Line Select: Monthly recommendations of one exceptional stock with superior profit potential and a favorable risk/reward ratio [3] - Value Line Special Situations Service: Monthly recommendations of small and mid-cap stocks expected to deliver returns above the market average [3] - Value Line Select ETFs: Monthly identification of one ETF positioned to outperform the market [3] - Value Line Select: Dividend Income & Growth: Monthly recommendations of two stocks expected to provide above-average current income and long-term dividend growth [4] - New Value Line ETFs Service: Analysis on over 2,800 ETFs to assist subscribers in portfolio selection [4] - Value Line M&A Service: Monthly highlight of one company as a potential acquisition target at a material premium [5] - Value Line Information You Should Know: Focuses on financial planning and investment issues relevant to today's investors [5] - Value Line Climate Change Investing Service: Targets climate change as a critical issue expected to transform the global economy [6] Research Products - Value Line Investment Survey: Provides financial information and quantitative analysis on approximately 1,800 small and mid-cap companies [8] - Value Line 600: In-depth research on 600 large and prominent companies [8] - Value Line Investment Survey–Selection & Opinion: Weekly economic and stock market commentary with actively managed model portfolios [8] - Value Line Investment Analyzer: Covers large, mid, and small-cap stocks, comprising about 90% of the U.S. stock market [10]

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The clinical research arena is experiencing transformative advancements due to the successful application of Generative AI (GenAI) tools, enhancing efficiency and quality in clinical trials [4][6] - Regulatory agencies, including the FDA, are beginning to establish guidelines for the responsible use of AI in clinical studies [6] - The report emphasizes a multi-pronged approach to safeguard efficiency and quality in clinical trials through various AI methodologies [19] Overview - The report highlights the increasing anticipation among industry professionals regarding the potential of AI to improve clinical trials and healthcare [4] - There are numerous opportunities to leverage AI technologies across the clinical trial ecosystem, including design, patient engagement, and regulatory submissions [5] AI Methodologies - Distinction is made between Generative AI, which generates responses based on training data, and agentic AI, which independently handles complex problems [10][11] - A holistic approach is necessary for developing AI frameworks, emphasizing the importance of training, ethical considerations, and human oversight [12][13] Safeguards for AI in Clinical Trials - Five critical categories of safeguards are identified to ensure the safe and efficient use of AI in clinical studies: curating and containerizing data, integrating "human-in-the-loop," harmonization of response, objectivity, and recognizing uncertainty [19][20] - Curating training data is essential to avoid poor-quality responses and ensure reliability in clinical operations [24][25] - The integration of human oversight is crucial to optimize quality and prevent erroneous outputs from AI systems [26][29] Use Cases of AI in Clinical Trials - The report discusses successful applications of AI, including a scientific Q&A chatbot used in a Phase III trial, which improved the efficiency of protocol clarifications and reduced the burden on medical monitors [39][40] - The chatbot's success was attributed to rigorous training, harmonized responses, and the ability to recognize knowledge gaps [41][42]

Core Insights - WuXi Biologics has successfully completed Asia's first commercial-scale Process Performance Qualification (PPQ) campaign for 5,000L single-use bioreactors, marking a significant advancement in biomanufacturing capabilities [1][3] - The company achieved a nearly 70% reduction in protein production costs per gram and a 20% increase in protein yield per batch through innovative process technologies [2][7] - The MFG20 facility's total capacity has increased from 8,000L to 23,000L by integrating three 5,000L single-use bioreactors with existing production lines [2][3] Company Achievements - WuXi Biologics has maintained a 99% production success rate over the past three years across over 300 batches of scaled production, demonstrating its leadership in commercial biomanufacturing [3] - The MFG20 facility has achieved a 100% PPQ success rate and holds ISO 14001 and ISO 45001 certifications, underscoring its operational excellence [3] - The company supports 817 integrated client projects, including 21 in commercial manufacturing, showcasing its extensive engagement in the biopharmaceutical sector [5] Sustainability and Innovation - WuXi Biologics emphasizes sustainability as a cornerstone of its long-term growth strategy, driving green technology innovations to provide advanced end-to-end Green CRDMO solutions [6] - The company is committed to fostering positive social and environmental impacts through responsible practices and collaboration with stakeholders [6]

居民财富管理需求加速升级，买方投顾模式已是行业转型的核心。然而，公募基金产品不断涌现，投资 者投资平台分散化，全市场持仓信息难以统一... 理财师如何从海量数据中提炼客户真实需求，并为投资者高效提供科学的资产配置方案？ 晨星基金E账户诊断服务 通过与基金E账户的深度对接，实现账户便捷同步、实时净值更新、全面持仓 诊断的功能升级，助力理财师一站式洞察投资者的基金资产分布，并用标准化工具为投资者提供更精 准、个性化的资产配置建议。 分享要点 本次晨星线上分享会上，晨星产品经理苏圳鹏将分享从账户诊断到资产配置的全流程实操，直击业务刚 需。 1 借助基金E账户，洞察客户全面真实持仓 分享嘉宾 参会方式 主讲人：苏圳鹏 晨星中国产品经理 2 如何将E账户诊断结果应用于配置建议 3 结合客户风险偏好，实现个性化资产配置 时间： 2025年4月24日（星期四）15:30-17:30 分享形式： 腾讯会议 报名方式： 扫描 下方 二维码 或点击文末 阅读原文 进行报名！ * 报名截止日期为 2025 年 4 月 24 日中午 12:00 ，审核通过后我们将以邮件形式为您发送报名成功提醒和参会信息。 如有更多疑问或需求，欢迎邮 ...